Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 5/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | JUN | P05412 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202270 | 0.79 | HTR2A (0.40) | MAPK14THRBTGFBR1 | |
| SCHEMBL21158689 | 0.78 | HTR2A (0.39) | EIF2AK2MAPK14THRBTGFBR1 | |
| SCHEMBL18202323 | 0.75 | HTR2A (0.39) | TGFBR1 | |
| SCHEMBL29571670 | 0.75 | HTR2A (0.39) | TGFBR1 | |
| SCHEMBL29571431 | 0.75 | CDK9 (0.43) | PDPK1 | |
| SCHEMBL19921275 | 0.73 | EGFR (0.43) | MKNK1MKNK2EGFR | |
| SCHEMBL21158687 | 0.73 | EGFR (0.45) | EGFR | |
| SCHEMBL28378854 | 0.72 | EGFR (0.43) | EGFR | |
| SCHEMBL21227299 | 0.72 | EGFR (0.41) | EGFR | |
| SCHEMBL28362602 | 0.72 | EGFR (0.39) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | EIF2AK2 1607/4885MAPK9 22/4885MAPK10 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.